潤都股份(002923.SZ):降壓藥奧美沙坦酯片獲批上市
格隆匯6月28日丨潤都股份(002923.SZ)宣佈,公司近日收到國家藥監局簽發的關於奧美沙坦酯片(40mg)的《藥品註冊批件》。奧美沙坦酯片適用於高血壓的治療。
公司於2020年2月18日向國家藥監局藥品審評中心遞交了奧美沙坦酯片藥品註冊申請,並獲得受理。公司奧美沙坦酯片以化學藥品註冊分類4類獲批上市,標誌着此產品視同通過仿製藥一致性評價,將對公司的市場拓展帶來積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.